Lawrence Park, AM, MD presented to the U.S. Food and Drug Administration Neurological Devices Panel examining the reclassification of electroconvulsive therapy (ECT) devices on January 27, 2011. These are his remarks describing a research literature review of the risks and primary side effects of ECT, as published in the public record of the meeting.
Key risks are defined as substantial risks of device use that could significantly influence the risk/benefit profile of the device. Mitigating factors may potentially serve as regulatory controls to adequately reduce the risk of device use such that a reasonable assurance of safety and effectiveness can be demonstrated for the device.
Like the determination of potentially significant adverse events discussed in the safety review, the identification of key risks is based on similar criteria, that is, they are substantiated by a comprehensive review of all sources of data, there is sufficient evidence of significant frequency and severity, and there’s evidence of being associated with ECT device use. [...]
The key risks of ECT are presented in this slide and reorganized into three different main categories.
The first category, medical and physical risks includes adverse reaction to anesthetic agents and neuromuscular blocking agents, alterations in blood pressure, cardiovascular complications, death, dental and oral trauma, pain and discomfort, physical trauma, prolonged seizures, pulmonary complications, skin burns, and stroke. The other two main categories include cognitive and memory dysfunction, and device malfunction. [...]
Again, here’s the list of proposed key risks. The Panel will be asked if this is a complete and accurate list of the key risks presented by ECT and asked to comment on whether you disagree with the inclusion of any of these risks or whether you believe any other risks are among the key risks presented by ECT.
Key Risks and Mitigating Factors of ECT
I’ll now present an examination of each key risk and potential mitigating factors by reviewing this table which goes over the next three slides.
Adverse reactions to anesthesia are rare but potentially severe complications associated with ECT. These reactions are related to the use of anesthetic agents and neuromuscular blocking agents to which patients may have rare but potentially severe reactions. Potential mitigating factors may consist of pre-ECT assessment, including pertinent medical and surgical history, family history of reaction to anesthetic agents, physical exam, as well as appropriate procedure monitoring and clinical management to any reaction that may arise.
Alterations in blood pressure are common but typically benign complications associated ECT. Hypertension as well as hypotension may be associated with ECT treatment. Potential mitigating factors include pre-ECT assessment of medical, particularly cardiovascular status, appropriate procedure monitoring, and clinical management.
Cardiovascular complications are uncommon but potentially severe complications of ECT treatment. They most commonly include arrhythmias and/or ischemia. Cardiovascular complications are one of the most frequent causes of morbidity and mortality associated with ECT. Potential mitigating factors for cardiovascular complications include pre-ECT assessment which may include blood pressure assessment, pre-ECT electrocardiogram, echocardiogram or Holter monitoring, appropriate procedure monitoring, and clinical management.
Death is a rare but severe outcome of ECT treatment. It is a result of various complications of ECT such as reactions to anesthesia, cardiovascular complications, pulmonary complications, or stroke. Potential mitigating factors include those proposed for each of these key risks.
Dental and oral trauma including dental fractures, dislocations, lacerations, and prosthetic damage are uncommon complications of ECT and are generally of mild to moderate severity. Potential mitigating factors may include pre-ECT dental assessment, removal of prostheses, as well as the use of mouth protection or bite blocks during the procedure.
Pain and discomfort are common but generally mild to moderate complications of ECT. They are typically treated with the use of as-needed analgesic medication.
Physical trauma associated with ECT, they include fractures and soft tissue injury. Physical trauma usually occurs as a consequence of significant muscle contraction during the treatment. Though more prevalent in previous years of ECT use, in current practice, this key risk is uncommon. Potential mitigating factors to prevent or reduce the severity of physical trauma include the use of general anesthetic agents and neuromuscular blocking agents. 189
Prolonged seizures are an uncommon and moderate to severe complication of ECT. Status epilepticus may ensue if prolonged seizures are not properly treated. Potential mitigating factors include an appropriate pre-ECT neurological assessment as well as EEG monitoring during the procedure and the availability of rapid treatment of prolonged seizures should they occur.
Pulmonary complications, such as prolonged apnea or aspiration, are rare but potentially severe complications of ECT. With cardiovascular complications, they represent one of the most common causes of morbidity and mortality associated with ECT. Potential mitigating factors include appropriate pre-ECT assessment of pulmonary function, pre- ECT tests such as chest x-ray and pulmonary function test, and appropriate monitoring and clinical management before, during, and after the procedure.
Skin burns are uncommon and typically mild complications of ECT. They most commonly occur when there’s poor contact of the electrode with the skin surface resulting in high impedance in the electrical circuit. Skin burns may be mitigated by proper skin preparation, electrode contact, including the use of conductivity gel.
Stroke is a rare and potentially severe complication that may be associated with ECT. Potential mitigating factors include pre-ECT assessment of risk factors for stroke, including possible neuroimaging or cardiovascular and neurovascular assessment when appropriate, appropriate procedure monitoring, and clinical management during the treatment.
The issue of inadequate informed consent processes and/or forced treatment has been raised in the public docket, in the MAUDE database, and in the published literature. Critics of the informed consent process claim that if individuals are inadequately or inaccurately informed of the risks of ECT, the risk/benefit assessment is altered.
One potential mitigating factor for inadequate consent is the requirement of a more rigorous informed consent process. Such a process would help to ensure that the patient is making a fully informed decision about receiving treatment. The process would consist of outlining a more rigorous consent process in the user labeling of the device that would require the use of an additional checklist in addition to standard written informed consent procedure. This checklist would contain all known risks of device usage, the likelihood of occurrence, and the potential severity.
During the process, the treating physician and patient would be required to review each item with both parties signing off to acknowledge discussion of the item. This checklist could then be kept with the standard written informed consent documentation, and the criteria for patient capacity to consent to treatment and perform the acceptance of risk through this process would remain unchanged. Acceptance of risk checklist may be a useful special control for addressing the risks of ECT device use. Within FDA, there’s precedence for requiring such additional informed consent requirements.
Please keep this discussion of key risks and potential mitigating factors in mind in your deliberations of the following question regarding whether the medical and physical risks of ECT can be adequately mitigated. [...]
Lawrence Park, AM, MD. (2011). Risks and Side Effects of ECT. Psych Central. Retrieved on July 28, 2014, from http://psychcentral.com/lib/risks-and-side-effects-of-ect/0007365
Last reviewed: By John M. Grohol, Psy.D. on 30 Jan 2013
Published on PsychCentral.com. All rights reserved.